MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
MiRXES secures two trophies at the SBR Management Excellence Awards 2021
The company was awarded the Team of the Year and Executive of the Year awards for Biotechnology.
Read Here
Advertise
Sign Up
![[Singapore Business Review] Report on the Asian Business Channel](https://www.cmgassets.com/s3fs-public/styles/video_thumbnail/public/2026-10/full-show-thumbnail_1.png.webp?VersionId=bJbrT_JKOuMWBnf7YkmsWjOSWIXddSvY&itok=zWuxHRNG)
Commentary
When scale arrives before proof: Singapore’s capital allocation question in Southeast Asia
Rethinking fleet ownership in a changing business landscape
Beyond the chips: The materials behind Singapore’s AI infrastructure
How homegrown brands are redefining premium in Asia
AI in hospitality: Where should Singapore’s F&B operators draw the line?
Do Singapore workplaces mistake silence for leadership?
AI as the new competitive advantage for Singapore’s small retailers
Singapore's next payments opportunity